4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 5.2% – Here’s What Happened

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s stock price rose 5.2% during trading on Tuesday . The company traded as high as $10.78 and last traded at $10.9650. Approximately 101,193 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 767,988 shares. The stock had previously closed at $10.42.

Analysts Set New Price Targets

FDMT has been the topic of several analyst reports. Royal Bank Of Canada lifted their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, March 20th. Chardan Capital reaffirmed a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $29.88.

4D Molecular Therapeutics Price Performance

The business has a 50 day moving average of $9.50 and a 200 day moving average of $9.13. The company has a market cap of $607.49 million, a PE ratio of -4.52 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The company had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. Sell-side analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.8 EPS for the current fiscal year.

Insider Buying and Selling at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the transaction, the insider owned 942,485 shares in the company, valued at approximately $9,867,817.95. This represents a 10.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in 4D Molecular Therapeutics in the first quarter worth $46,000. Millennium Management LLC increased its stake in shares of 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after acquiring an additional 213,264 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in 4D Molecular Therapeutics during the 1st quarter valued at about $39,000. American Century Companies Inc. lifted its position in 4D Molecular Therapeutics by 11.5% during the 2nd quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock valued at $181,000 after acquiring an additional 5,026 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in 4D Molecular Therapeutics by 11.7% during the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after acquiring an additional 2,284 shares in the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.